JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2005;58:1046-1050; doi:10.1136/jcp.2004.024919
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farabegoli, F
Right arrow Articles by Taffurelli, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farabegoli, F
Right arrow Articles by Taffurelli, M
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer

ORIGINAL ARTICLE

Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma

F Farabegoli1, C Ceccarelli2, D Santini2, M Taffurelli3

1 Department of Experimental Pathology, University of Bologna, Via San Giacomo, 14, 40126 Bologna, Italy
2 Institute of Anatomical and Pathological Histology, University of Bologna
3 Breast Cancer Surgical Unit, First Surgical Clinic, University of Bologna

Correspondence to:
Dr F Farabegoli
Department of Experimental Pathology, University of Bologna, Via San Giacomo, 14, 40126 Bologna, Italy; frbfl{at}alma.unibo.it Aims: To investigate SOCS-2 (suppressor of cytokine signalling 2) protein expression in breast carcinoma samples in relation to biopathological parameters and survival.

Methods: A polyclonal antibody against SOCS-2 was used to study 50 archival breast carcinoma samples, collected from 1993 to 1995. The presence of SOCS-2 protein was investigated in relation to clinical and biological parameters used in breast cancer pathology. Fluorescence in situ hybridisation (FISH) was used to study whether SOCS-2 expression was related to SOCS-2 gene copy number.

Results: SOCS-2 protein was expressed in 34 of 50 breast carcinoma samples and was positively associated with low grade, low nuclear grade, and p27 protein. SOCS-2 expression was inversely related to Ki-67, cyclin A, retinoblastoma protein (pRb), and the epidermal growth factor receptor (EGFR). No relation with overall survival was demonstrated. SOCS-2 amplification was found in three samples. No relation between the number of FISH signals and SOCS-2 expression was found.

Conclusions: The significant correlation seen between SOCS-2 expression, grade, nuclear grade, p27, Ki-67, cyclin A, pRb, and EGFR labelling strongly supports the hypothesis that SOCS-2 loss might be related to cell proliferation and tumour growth in breast carcinoma. Gene copy number changes did not seem to play a role in SOCS-2 regulation and expression; other mechanisms might be involved and deserve further study.


Abbreviations: CIS, cytokine induced SRC homology 2 SH2 protein; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; %LIa, percentage of the labelled nuclear area over the total neoplastic nuclear area; OS, overall survival; PR, progesterone receptor; pRb, retinoblastoma protein; SOCS, suppressor of cytokine signalling

Keywords: breast carcinoma; fluorescence in situ hybridisation; suppressor of cytokine signalling 2; biopathological variables; prognosis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.